Xylocaine (Lidocaine) Toxicity

What is Xylocaine (lidocaine) toxicity?

Xylocaine is the brand name for lidocaine, a local‑anesthetic and anti‑arrhythmic drug that works by blocking sodium channels in nerve membranes. Lidocaine toxicity occurs when the concentration of lidocaine in the bloodstream rises above the level that the body can safely metabolize, leading to neurologic, cardiovascular, and sometimes systemic effects. Toxicity can be acute—usually after an inadvertent overdose or rapid intravascular injection—or chronic, after repeated dosing in patients with impaired metabolism (e.g., liver disease). Recognizing the signs early is essential because severe toxicity can cause seizures, cardiac arrest, or death.

Sources: Mayo Clinic, CDC, NIH.

Common Causes

The following situations are most frequently associated with lidocaine toxicity:

• Accidental intravascular injection during dental, dermatologic, or peripheral nerve blocks.
• Excessive dose – exceeding the maximum recommended dose (typically 4.5 mg/kg without epinephrine, 7 mg/kg with epinephrine).
• Rapid bolus administration in emergency settings (e.g., for ventricular arrhythmias).
• Use of high‑concentration formulations (e.g., 2 % or 4 % solutions for topical use).
• Impaired hepatic function – liver disease reduces lidocaine metabolism.
• Renal insufficiency – accumulation of metabolites can potentiate toxicity.
• Drug interactions – medications that inhibit CYP3A4 or CYP1A2 (e.g., cimetidine, erythromycin) increase lidocaine levels.
• Pregnancy – altered plasma protein binding can raise free lidocaine.
• Severe anemia or hypoproteinemia – less protein binding leads to higher free drug.
• Repeated topical application of lidocaine patches or gels over large skin areas.

Associated Symptoms

Lidocaine toxicity typically follows a predictable progression, beginning with early neurologic signs and advancing to cardiovascular collapse if untreated.

• Neurologic: tingling or “pins‑and‑needles” (paresthesia), circumoral numbness, metallic taste, dizziness, visual disturbances, tinnitus, confusion, agitation.
• Seizure activity: tonic‑clonic seizures are the most common severe neurologic manifestation.
• Cardiovascular: hypotension, bradycardia, widened QRS complex, ventricular tachycardia/fibrillation, asystole.
• Respiratory: respiratory depression, apnea (often secondary to seizures or cardiac compromise).
• Gastrointestinal: nausea, vomiting.

When to See a Doctor

Because lidocaine toxicity can progress quickly, seek medical attention promptly if you experience any of the following after a lidocaine‑containing procedure or product:

• Feeling of “numbness” around the mouth or tongue.
• Sudden tingling, numbness, or a metallic taste.
• Dizziness, visual changes, or confusion.
• Any seizure‑like activity, even if it stops quickly.
• Rapid heartbeat, chest pain, or fainting.
• Severe headache, difficulty breathing, or loss of consciousness.

Diagnosis

When a clinician suspects lidocaine toxicity, the evaluation includes:

1. History and physical exam – timing of lidocaine administration, dose, route, and observed symptoms.
2. Serum lidocaine level – drawn 5–15 minutes after the suspected peak; toxic levels >5 µg/mL (therapeutic 1‑5 µg/mL).
3. Electrocardiogram (ECG) – looking for widened QRS, PR prolongation, or arrhythmias.
4. Blood gases – to assess respiratory compromise and metabolic acidosis.
5. Liver function tests – especially in patients with known hepatic disease.
6. Urine toxicology – to rule out co‑ingestion of other CNS depressants.

In emergency settings, treatment is often initiated based on clinical presentation before lab results return.

Treatment Options

Management focuses on stabilizing the airway, stopping further absorption, and treating neurologic or cardiac complications.

Immediate (Emergency) Care

• Airway protection – endotracheal intubation if seizures or apnea occur.
• Seizure control – benzodiazepines (e.g., lorazepam 0.1 mg/kg IV) are first‑line; barbiturates if refractory.
• Cardiac support – intravenous lipid emulsion (ILE) therapy (20% lipid emulsion 1.5 mL/kg bolus, followed by infusion) has become standard for severe local‑anesthetic systemic toxicity (LAST) per American Society of Regional Anesthesia guidelines.
• Vasopressors – epinephrine for hypotension; consider amiodarone for refractory ventricular arrhythmias.

Supportive / Ongoing Care

• Continuous cardiac monitoring for at least 24 hours.
• IV fluids to maintain perfusion.
• Correction of metabolic acidosis with bicarbonate if pH <7.2.
• Observation in an intensive care unit for severe cases.

Home / Post‑Discharge Care

Most patients who survive an acute episode recover fully. Instructions may include:

• Avoiding further lidocaine exposure for at least 48 hours.
• Monitoring for delayed neurologic symptoms (e.g., memory problems).
• Follow‑up liver function testing if pre‑existing liver disease was a factor.

Prevention Tips

Preventing lidocaine toxicity centers on proper dosing, technique, and patient assessment.

• Calculate weight‑based maximum dose before every procedure.
• Use a test dose (e.g., 0.5 mL of 1% lidocaine) to confirm no intravascular placement.
• Inject slowly and aspirate before each increment.
• Prefer lower‑concentration solutions when large areas need anesthetization.
• Screen for hepatic or renal impairment and adjust dose accordingly.
• Review the patient’s medication list for CYP inhibitors.
• When using topical patches, limit total surface area to ≤10 % of body surface and adhere to maximum 12‑hour wear time.
• Educate patients to report early neurologic sensations (tongue numbness, metallic taste).
• Maintain resuscitation equipment (defibrillator, lipid emulsion) in any setting where lidocaine is administered.

Emergency Warning Signs

The following signs indicate a medical emergency requiring immediate emergency‑department care or calling 911.

• Severe or rapidly spreading numbness/tingling, especially around the mouth.
• Sudden confusion, agitation, or loss of consciousness.
• Any seizure activity, even if brief.
• Chest pain, palpitations, or a rapid, irregular heartbeat.
• Difficulty breathing, audible wheezing, or apnea.
• Blue‑tinged lips or skin (cyanosis).
• Vomiting with inability to protect the airway.

Prompt treatment dramatically reduces the risk of permanent neurologic injury or death.